- Home
- MATV vs XFOR Comparison
MATV vs XFOR Comparison
Compare MATV & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MATV | XFOR |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.1M | 407.5M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | MATV | XFOR |
|---|---|---|
| Price | $8.81 | $4.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 360.9K | 304.0K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.97 | N/A |
| Revenue Next Year | $4.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.03 | $1.35 |
| 52 Week High | $15.48 | $4.83 |
Technical Indicators
Market Signals| Indicator | MATV | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 57.03 |
| Support Level | $8.06 | $3.44 |
| Resistance Level | $8.95 | $4.57 |
| Average True Range (ATR) | 0.42 | 0.24 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 62.18 | 72.12 |
Price Performance
Historical ComparisonAbout MATV Mativ Holdings Inc.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.